- Poster presentation
- Open Access
Potential value of cartilage and bone soluble biomarkers in evaluating joint damage in juvenile idiopathic arthritis
© Pederzoli et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Joint Damage
- Bone Erosion
- Joint Space Narrowing
Serum biomarkers of bone and cartilage turnover were found to predict structural damage progression in Rheumatoid Arthritis (RA). Their potential value in Juvenile Idiopathic Arthritis (JIA) has never been explored.
1) To examine associations between soluble biomarkers of bone (CTX-I) and cartilage degradation (C1-2C, C2C) and joint damage as assessed by Conventional Radiography (CR) and Magnetic Resonance Imaging (MRI) in patients with JIA. 2) To investigate whether these biomarkers can predict structural damage progression.
The clinically more affected wrist of 88 JIA patients was studied with CR according to adapted Sharp/van der Heijde score (SHS) method and MRI by using the OMERACT RA-MRI-score, coupled with standard clinical assessment. One-year CR follow-up was available in 65 patients, whereas one-year MRI follow-up was available in 51 patients. Serum CTX-I, C1-2C, C2C were measured by ELISA assays in all patients at the enrollment and in gender- and age-matched healthy controls (N= 154).
Unlike adults with RA, CTX-I, C1,2C and C2C levels were significantly lower in JIA patients than healthy controls (P< 0.0001).
Biomarker levels did not correlate with clinical measure of disease activity and damage, disease duration and with Sharp/van der Heijde score (SHS), and RAMRIS bone erosion score.Median C1,2C and C2C were significantly higher in patients with structural damage progression according to JSN (joint space narrowing)-SHS score compared to patients without progression (C1,2C: 240 ng/ml vs 125 ng/ml, P=0.01; C2C: 133.7 ng/ml vs 65.7 ng/ml, P= 0.001). Unlike RA, patients with radiographic progression showed significantly lower levels of CTX-I (1.03 ng/ml) compared patients without structural damage progression (1.53 mg/ml P=0.03).Patients, who required either initiation of methotrexate or addition of a biologic agent at the 6 months follow-up visit, had significantly higher levels of C1,2C (P=0.027) and C2C (P=0.034) compared to patients who did not require treatment changes.
Our results suggest an inhibition of bone and cartilage turnover in patients with JIA. Biomarkers of cartilage degradation are promising as potential predictors of structural damage progression and severity of disease course.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.